Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1)

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 9, 2003, Pages 648-654

  Cetkovic Cvrlje, Marina ^a   Dragt, Angela L ^a   Uckun, Fatih M ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

4 (4 Hydroxyphenyl) amino 6,7 dimethoxyquinazoline; Diabetes, mouse, type 1; Islet allogeneic transplantation, allograft rejection; JANEX 1; Janus kinase 3; Protein tyrosine kinase, mouse; WHI P131

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; CYCLOSPORIN A; ENZYME; JANUS KINASE 3; QUINAZOLINE DERIVATIVE; STREPTOZOCIN; TACROLIMUS; UNCLASSIFIED DRUG; WHI P 132;

ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME DEFICIENCY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0141426807     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299807     Document Type: Article

References (37)

1. Hall, B. M., Cells mediating allograft rejection. Transplantation. 51, 1141 (1991)
2. Yun, S., Sawyer, G. J., Zhang, X. et al., The role of IL-2 in allograft rejection - A lesson learned from experimental work. Transplantation. 69, 2480 (2000)
3. Mueller, R., Davis, J. D., Krahl, T. et al., IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J. Immunol. 159, 1599 (1997)
4. Li, X. C., Roy-Chaudhury, P., Hancock, W. W. et al., IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection. J. Immunol. 161, 890 (1998)
5. Sugamura, K., Asao, H., Kondo, M. et al., The interleukin-2 receptor gamma-chain: its role in multiple cytokine receptor complexes and T cell development in XSCID. Annu. Rev. Immunol. 14, 179 (1996)
6. Ihle, J. N., Kerr, J. R., Jaks and Stats in signaling by the cytokine receptor superfamily. Trends. Genet. 11, 69 (1995)
7. Nosaka, T., van Deursen, J. M., Tripp, R. A. et al., Defective lymphoid development in mice lacking Jak3. Science 270, 800 (1995)
8. Park, S. Y., Saijo, K., Takahashi, T. et al., Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3, 771 (1995)
9. Thomis, D. C., Gurniak, C. B., Tivol, E. et al., Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 270, 794 (1995)
10. Leonard, W. J., O'Shea, J. J., Jaks and Stats: Biological implications. Annu. Rev. Immunol. 16, 293 (1998)
11. Cao, X., Shores, E. W., Hu Li, J. et al., Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 2, 223 (1995)
12. DiSanto, J. P., Muller, W., Guy Grand, D. et al., Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA. 92, 377 (1995)
13. Tomita, K., Saijo, K., Yamasaki, S. et al., Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex. J. Biol. Chem. 276, 25378 (2001)
14. Thomis, D. C., Aramburu, J., Berg, L. J., The JAKfamily tyrosine kinase JAK3 is required for IL-2 synthesis by naive/resting CD4+ T-cells. J. Immunol. 163, 5411 (1999)
15. Cetkovic-Cvrlje, M., Roers, B. A., Waurzyniak, B. et al., Targeting Janus Kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 98, 1607 (2001)
16. Kaplan, H. M., Sun, Y. L., Hoey, T. et al., Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382, 174 (1996)
17. Thierfelder, W. E., van Deursen, J. M., Yamamoto, K. et al., Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 382, 171 (1996)
18. Takeda, K., Tanaka, T., Shi, W. et al., Essential role of Stat6 in IL-4 signalling. Nature 380, 627 (1996)
19. Shimoda, K., Deursen, J. V., Sangster, M. Y. et al., Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380, 630 (1996)
20. Kaplan, M. H., Schindler, U., Smiley, S. T. et al., Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313 (1996)
21. Cetkovic-Cvrlje, M., Gerling, I. C., Muir, A. et al., Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta cell antigens. Diabetes 46, 1975 (1997)
22. Bridgett, M., Cetkovic-Cvrlje, M., O'Rourke, R. et al., Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic b-cells. Diabetes 47, 1848 (1998)
23. Sudbeck, E. A., Liu, X. P., Narla, R. K. et al., Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin. Cancer. Res. 5, 1569 (1999)
24. Guo, Z., Chong, A. S. F., Shen, J. et al., In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. Transplantation 63, 716 (1997)
25. Sutherland, D. E., Gruessner, R. W. G., Gruessner, A. C., Pancreas transplantation for treatment of diabetes mellitus. World J. Surg. 25, 487 (2001)
26. Boker, A., Rothenberg, L., Hernandez, C. et al., Human islet transplantation: update. World J. Surg. 25, 481 (2001)
27. Bretzel, R. G., Brendel, M., Eckhard, M. et al., Islet transplantation: present clinical situation and future aspects. Exp. Clin. Endocrinol. Diabetes 109, S384 (2001)
28. Shapiro, J. A. M., Ryan, E. A., Lakey, J. R. T., Pancreatic islet transplantation in the treatment of diabetes mellitus. Best. Pract. Res. Clin. Endocrinol. Metab. 15, 241 (2001)
29. Shapiro, A. M., Lakey, J. R. T., Ryan, E. A. et al., Islet transplantation in seven patients with Type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230 (2000)
30. Li, X. C., Zand, M. S., Li, Y. et al., On histocompatibility, Th1 to Th2 immune deviation, and the nature of the allograft responses. J. Immunol. 161, 2241 (1998)
31. Piccotti, R. J., Chan, S. Y., VanBuskirk, A. M. et al., Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 63, 619 (1997)
32. Nikolic, B., Lee, S., Bronson, R. T. et al., Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J. Clin. Invest. 105, 1289 (2000)
33. Kishimoto, K., Dong, V. M., Issazadeh, S. et al., The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106, 63 (2000)
34. Koglin, J., Glysing-Jensen, T., Gadiraju, S. et al., Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4. Circulation 101, 1034 (2000)
35. Strom, T. B., Roy-Chaudhury, P., Manfro, A. et al., The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol. 8, 688 (1996)
36. Uckun, F. M., Ek, O., Liu, X.-P. et al., In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]. Clin. Cancer. Res. 5, 2954 (1999)
37. Uckun, F. M., Roers, B. A, Waurzyniak, B. et al., Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 99, 4192 (2002)